Discovery of Azurin-Like Anticancer Bacteriocins from Human Gut Microbiome through Homology Modeling and Molecular Docking against the Tumor Suppressor p53

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Nguyen, Chuong ^a   Nguyen, Van Duy ^b  

^a TON DUC THANG UNIVERSITY   (Viet Nam)

^b Nha Trang University   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZURIN; BACTERIOCIN; PROTEIN P53;

ALGORITHM; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BIOINFORMATICS; CALCULATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROPHOBICITY; IMMUNE RESPONSE; IN VITRO STUDY; INTESTINE FLORA; LACTOBACILLUS SALIVARIUS; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NEISSERIA MENINGITIDIS; NONHUMAN; PREDICTIVE VALUE; PROTEIN STRUCTURE; PSEUDOMONAS AERUGINOSA; QUANTITATIVE ANALYSIS; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS; CHEMICAL PHENOMENA; EVALUATION STUDY; GASTROINTESTINAL TRACT; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; AZURIN; BACTERIOCINS; EVALUATION STUDIES AS TOPIC; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MOLECULAR DOCKING SIMULATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84973345153     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/8490482     Document Type: Article

References (44)

1. A. M. Chakrabarty, N. Bernardes, and A. M. Fialho, "Bacterial proteins and peptides in cancer therapy: today and tomorrow, " Bioengineered, vol. 5, no. 4, pp. 234-242, 2014.
2. B. S. Avner, A. M. Fialho, and A. M. Chakrabarty, "Overcoming drug resistance inmulti-drug resistant cancers and microorganisms: A conceptual framework, " Bioengineered, vol. 3, no. 5, pp. 262-270, 2012.
3. S. Felgner, D. Kocijancic, M. Frahm, and S. Weiss, "Bacteria in cancer therapy: renaissance of an old concept, " International Journal of Microbiology, vol. 2016, Article ID 8451728, 14 pages, 2016.
4. W. B. Coley, "II. Contribution to the knowledge of sarcoma, " Annals of Surgery, vol. 14, no. 3, pp. 199-220, 1891.
5. M. Riley, "Bacteriocins, biology, ecology, and evolution, " in Encyclopedia of Microbiology, pp. 32-44, Elsevier, New York, NY, USA, 2009.
6. G. Cornut, C. Fortin, and D. Soulières, "Antineoplastic properties of bacteriocins: revisiting potential active agents, " American Journal of Clinical Oncology, vol. 31, no. 4, pp. 399-404, 2008.
7. T. Yamada, M. Goto, V. Punj et al., "Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer, " Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 22, pp. 14098-14103, 2002.
8. T. Yamada, Y. Hiraoka, M. Ikehata et al., "Apoptosis or growth arrest: modulation of tumor suppressor p53's specificity by bacterial redox protein azurin, " Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 14, pp. 4770-4775, 2004.
9. T. Yamada, A. M. Fialho, V. Punj, L. Bratescu, T. K. Das Gupta, and A. M. Chakrabarty, "Internalization of bacterial redox protein azurin in mammalian cells: entry domain and specificity, " Cellular Microbiology, vol. 7, no. 10, pp. 1418-1431, 2005.
10. L. Jia, G. S. Gorman, L. U. Coward et al., "Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination, " Cancer Chemotherapy and Pharmacology, vol. 68, no. 2, pp. 513-524, 2011.
11. V. De Grandis, A. R. Bizzarri, and S. Cannistraro, "Docking study and free energy simulation of the complex between p53 DNA-binding domain and azurin, " Journal of Molecular Recognition, vol. 20, no. 4, pp. 215-226, 2007.
12. M. Taranta, A. R. Bizzarri, and S. Cannistraro, "Probing the interaction between p53 and the bacterial protein azurin by single molecule force spectroscopy, " Journal ofMolecular Recognition, vol. 21, no. 1, pp. 63-70, 2008.
13. M. Taranta, A. R. Bizzarri, and S. Cannistraro, "Modeling the interaction between the N-terminal domain of the tumor suppressor p53 and azurin, " Journal of Molecular Recognition, vol. 22, no. 3, pp. 215-222, 2009.
14. A. Chaudhari, A. M. Fialho, D. Ratner et al., "Azurin, Plasmodium falciparum malaria and HIV/AIDS: inhibition of parasitic and viral growth by azurin, " Cell Cycle, vol. 5, no. 15, pp. 1642-1648, 2006.
15. A. Naguleswaran, A. M. Fialho, A. Chaudhari, C. S. Hong, A. M. Chakrabarty, and W. J. Sullivan Jr., "Azurin-like protein blocks invasion of Toxoplasma gondii through potential interactions with parasite surface antigen SAG1, " Antimicrobial Agents and Chemotherapy, vol. 52, no. 2, pp. 402-408, 2008.
16. A. M. Fialho, N. Bernardes, and A. M. Chakrabarty, "Recent patents on live bacteria and their products as potential anticancer agents, " Recent Patents on Anti-Cancer Drug Discovery, vol. 7, no. 1, pp. 31-55, 2012.
17. J.-H. Cho, M.-H. Lee, Y.-J. Cho, B.-S. Park, S. Kim, and G.-C. Kim, "The bacterial protein azurin enhances sensitivity of oral squamous carcinoma cells to anticancer drugs, " Yonsei Medical Journal, vol. 52, no. 5, pp. 773-778, 2011.
18. C. Hetz, M. R. Bono, L. F. Barros, and R. Lagos, "MicrocinE492, a channel-forming bacteriocin from Klebsiella pneumoniae, induces apoptosis in some human cell lines, " Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 5, pp. 2696-2701, 2002.
19. V. D. Nguyen and H. H. C. Nguyen, "Molecular screening of azurin-like anticancer bacteriocins from human gut microflora using bioinformatics, " in Advances in Intelligent Systems and Computing, pp. 219-229, Springer, Berlin, Germany, 2015.
20. S. Schloissnig, M. Arumugam, S. Sunagawa et al., "Genomic variation landscape of the human gut microbiome, " Nature, vol. 493, no. 7430, pp. 45-50, 2013.
21. A. J. vanHeel, A. de Jong, M. Montalbán-López, J. Kok, andO. P. Kuipers, "BAGEL3: Automated identification of genes encoding bacteriocins and (non-)bactericidal posttranslationally modified peptides, " Nucleic Acids Research, vol. 41, pp. W448-W453, 2013.
22. L. J. Jensen, R. Gupta, N. Blom et al., "Prediction of human protein function from post-translational modifications and localization features, " Journal of Molecular Biology, vol. 319, no. 5, pp. 1257-1265, 2002.
23. L. J. Jensen, R. Gupta, H.-H. Stærfeldt, and S. Brunak, "Prediction of human protein function according to Gene Ontology categories, " Bioinformatics, vol. 19, no. 5, pp. 635-642, 2003.
24. T. M. Karpínski and A. K. Szkaradkiewicz, "Anticancer peptides from bacteria, " Bangladesh Journal of Pharmacology, vol. 8, no. 3, pp. 343-348, 2013.
25. J. Yang and Y. Zhang, "I-TASSER server: new development for protein structure and function predictions, " Nucleic Acids Research, vol. 43, no. 1, pp. W174-W181, 2015.
26. J. Ko, H. Park, L. Heo, and C. Seok, "GalaxyWEB server for protein structure prediction and refinement, " Nucleic Acids Research, vol. 40, no. 1, pp. W294-W297, 2012.
27. D. Xu and Y. Zhang, "Improving the physical realism and structural accuracy of protein models by a two-step atomiclevel energy minimization, " Biophysical Journal, vol. 101, no. 10, pp. 2525-2534, 2011.
28. V. B. Chen, W. B. Arendall III, J. J. Headd et al., "MolProbity: Allatom structure validation for macromolecular crystallography, " Acta Crystallographica, Section D: Biological Crystallography, vol. 66, no. 1, pp. 12-21, 2010.
29. A. C. Joerger, H. C. Ang, and A. R. Fersht, "Structural basis for understanding oncogenic p53 mutations and designing rescue drugs, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 41, pp. 15056-15061, 2006.
30. S. R. Comeau, D. W. Gatchell, S. Vajda, and C. J. Camacho, "ClusPro: An automated docking and discrimination method for the prediction of protein complexes, " Bioinformatics, vol. 20, no. 1, pp. 45-50, 2004.
31. D. J. Naisbitt, S. F. Gordon, M. Pirmohamed, and B. K. Park, "Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment, " Drug Safety, vol. 23, no. 6, pp. 483-507, 2000.
32. D. G. Lee, K.-S. Hahm, Y. Park et al., "Functional and structural characteristics of anticancer peptide Pep27 analogues, " Cancer Cell International, vol. 5, article 21, 2005.
33. Y.-B. Huang, X.-F. Wang, H.-Y. Wang, Y. Liu, and Y. Chen, "Studies on mechanism of action of anticancer peptides by modulation of hydrophobicity within a defined structural framework, " Molecular Cancer Therapeutics, vol. 10, no. 3, pp. 416-426, 2011.
34. A. M. Chakrabarty, "Bacterial proteins: A new class of cancer therapeutics, " Journal of Commercial Biotechnology, vol. 18, no. 1, 2012.
35. A. Bolhassani, "Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer, " Biochimica et Biophysica Acta, vol. 1816, no. 2, pp. 232-246, 2011.
36. A. Suau, R. Bonnet, M. Sutren et al., "Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut, " Applied and EnvironmentalMicrobiology, vol. 65, no. 11, pp. 4799-4807, 1999.
37. S. Wu, J. Skolnick, and Y. Zhang, "Ab initio modeling of small proteins by iterative TASSER simulations, " BMC Biology, vol. 5, article 17, 2007.
38. S. Singh, K. Chaudhary, S. K. Dhanda et al., "SATPdb: A database of structurally annotated therapeutic peptides, " Nucleic Acids Research, vol. 44, no. 1, pp. D1119-D1126, 2016.
39. T. Yamada, K. Christov, A. Shilkaitis et al., "P28, A first in class peptide inhibitor of cop1 binding to p53, " British Journal of Cancer, vol. 108, no. 12, pp. 2495-2504, 2013.
40. A. S. Hauser and B. Windshügel, "LEADS-PEP: A benchmark data set for assessment of peptide docking performance, " Journal of Chemical Information andModeling, vol. 56, no. 1, pp. 188-200, 2016.
41. R. Rentzsch and B. Y. Renard, "Docking small peptides remains a great challenge: An assessment using AutoDock Vina, " Briefings in Bioinformatics, vol. 16, no. 6, pp. 1045-1056, 2015.
42. F. Shaikh, P. Abhinand, and P. Ragunath, "Identification & Characterization of lactobacillus salavarius bacteriocins and its relevance in cancer therapeutics, " Bioinformation, vol. 8, no. 13, pp. 589-594, 2012.
43. M. A. Warso, J. M. Richards, D. Mehta et al., "A first-inclass, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumors, " British Journal of Cancer, vol. 108, no. 5, pp. 1061-1070, 2013.
44. Y. Zhang, Y. Zhang, L. Xia et al., "Escherichia coli Nissle 1917 targets and restrains mouse b16 melanoma and 4T1 breast tumors through expression of azurin protein, " Applied and EnvironmentalMicrobiology, vol. 78, no. 21, pp. 7603-7610, 2012.